Alba María Fernández González

Dr. Alba María Fernández González

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
AGAlba María Fernández González
Alba María Fernández González
DPDavid Sebastián Poveda
David Sebastián Poveda
EREloisa Ruiz
Eloisa Ruiz
EÁEnriqueta Álvarez
Enriqueta Álvarez
FGFrancisco Javier González
Francisco Javier González
AÁAntonio Álvarez-Kindelán
Antonio Álvarez-Kindelán

1 January 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
EREloisa Ruiz
Eloisa Ruiz
PMPaula Moreno
Paula Moreno
DPDavid Sebastián Poveda
David Sebastián Poveda
AGAlba María Fernández González
Alba María Fernández González
FGFrancisco Javier González
Francisco Javier González
AÁAntonio Álvarez-Kindelán
Antonio Álvarez-Kindelán

7 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EREloisa Ruiz
Eloisa Ruiz
PMPaula Moreno
Paula Moreno
FGFrancisco Javier Gonzalez
Francisco Javier Gonzalez
AGAlba María Fernández González
Alba María Fernández González
BCBenito Cantador
Benito Cantador
AÁAntonio Álvarez-Kindelán
Antonio Álvarez-Kindelán
(1) Background: Malignancies are an important cause of mortality after solid organ transplantation. The purpose of this study was to analyze the incidence of malignancies in patients receiving lung transplants (LT) and their influence on patients’ survival. (2) Methods: Review of consecutive LT from 1994 to 2021. Patients with and without malignancies were compared by univariable and multivariable analyses. Survival was compared with Kaplan-Meier and Cox regression analysis. (3) Results: There were 731 LT malignancies developed in 91 patients (12.4%) with related mortality of 47% (n = 43). Native lung cancer, digestive and hematological malignancies were associated with higher lethality. Malignancies were more frequent in males (81%; p = 0.005), transplanted for emphysema (55%; p = 0.003), with cyclosporine-based immunosuppression (58%; p < 0.001), and receiving single LT (65%; p = 0.011). Survival was worse in patients with malignancies (overall) and with native lung cancer. Risk factors for mortality were cyclosporine-based immunosuppression (OR 1.8; 95%CI: 1.3–2.4; p < 0.001) and de novo lung cancer (OR 2.6; 95%CI: 1.5–4.4; p < 0.001). (4) Conclusions: Malignancies are an important source of morbidity and mortality following lung transplantation that should not be neglected. Patients undergoing single LT for emphysema are especially at higher risk of mortality due to lung cancer in the native lung.

29 May 2025 in Interdisciplinary CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
AGAlba María Fernández González
Alba María Fernández González
JMJose R Matilla
Jose R Matilla
OPOrsolya Anna Pipek
Orsolya Anna Pipek
LSLaura Gonzalez Sanchez
Laura Gonzalez Sanchez
MBMerjem Begic
Merjem Begic
CAClemens Aigner
Clemens Aigner
OBJECTIVES: Our study aimed to evaluate factors influencing perioperative and long-term outcomes of patients undergoing curative-intent chest wall resection and reconstruction. METHODS: A retrospective single-centre analysis was conducted on all patients undergoing curative-intent chest wall resection and reconstruction from 2010 to 2023. Perioperative outcome was analysed for the entire cohort. Overall survival and disease-free survival were analysed using the Kaplan–Meier method and log-rank test and multivariable Cox proportional hazards regression models with a particular focus on patients with lung cancer and chest wall involvement. RESULTS: A total of 143 consecutive patients (median age 62 years, 44.1% females) were included, and 75% of patients received perioperative systemic therapy or radiation. Rib resection alone was performed in 69.9%, additional sternal resection in 16.1%, spine resection in 11.9% and clavicle resection in 2.1%. Additional resections included the lung (n = 75), diaphragm (n = 6), pericardium (n = 2), subclavian vein (n = 2), pulmonary artery (n = 1) and multiple structures (n = 22). Reconstruction was performed using synthetic protheses (n = 89), metallic (n = 6) or combinations of materials (n = 32). Median tumour diameter was 10 cm; 88% were malignant. Local recurrence rate was 9.5%. Median disease-free survival (86 events) was 36 months, and median overall survival (62 events) was 80 months. The 5-year disease-free survival and overall survival were 54.1% and 74.1%, respectively. In patients with lung cancer, overall survival was significantly affected by age (P = 0.028), histology (P < 0.001), resection size >10 cm (P = 0.018), postoperative performance status (P < 0.001) and postoperative complications (P < 0.001) in multivariable analysis and disease-free survival by postoperative performance status (P < 0.001). CONCLUSIONS: Postoperative performance status is correlated with overall survival after chest wall resection.

1 January 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
DPDavid Poveda
David Poveda
EREloisa Ruiz
Eloisa Ruiz
AGAlba María Fernández González
Alba María Fernández González
FGFrancisco Javier Gonzalez
Francisco Javier Gonzalez
PMPaula Moreno
Paula Moreno
AÁAntonio Álvarez-Kindelán
Antonio Álvarez-Kindelán